Por: ABC News Health May 16, 2023
The U.S. is attempting to block the proposed acquisition of Horizon Therapeutics for more than $26 billion by biotech drug developer Amgen on antitrust grounds. The Federal Trade Commission said Tuesday that the deal, announced in December, would give Amgen unfair leverage to block competition for Horizon medications. The FTC said the deal would entrench Horizon’s monopoly position on treatments for thyroid eye disease and chronic refractory... + full article
The Boston Globe USA Tech May 17, 2023
The Federal Trade Commission on Tuesday sued to block drugmaker Amgen’s $27.8 billion acquisition of pharmaceutical company Horizon Therapeutics, saying it would thwart competition in the drug industry.The FTC said the deal would allow Amgen to exploit a maneuver known as... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | Associated Press
Amgen to buy Horizon Therapeutics in $26.4B deal | 10 WBNS
ABC News USA Business May 16, 2023
The U.S. is attempting to block the proposed acquisition of Horizon Therapeutics for more than $26 billion by biotech drug developer Amgen on antitrust grounds. The Federal Trade Commission said Tuesday that the deal, announced in December, would give Amgen unfair leverage to... + más
Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon | ABC News
Monopoly concerns push FTC to sue to block Amgen's more than $26B deal for Horizon | Associated Press
Los Angeles Times USA Business May 16, 2023
The Federal Trade Commission sued Tuesday to block Amgen's $27.8-billion deal to buy Horizon Therapeutics, arguing the tie-up would stifle competition for the development of treatments for serious illnesses. In a sealed complaint filed in Illinois federal court, the FTC... + más
Associated Press USA Health May 16, 2023
The Hill USA Politics May 16, 2023
Associated Press USA Business December 12, 2022
Amgen is spending more than $26 billion to dive deeper into rare disease treatments with a deal for drugmaker Horizon Therapeutics. The biotech drug developer said Monday that it will pay $116.50 in cash for each share of Horizon, which makes a thyroid eye disease treatment that... + más
Amgen to buy Horizon Therapeutics in $26.4B deal | ABC News
10 WBNS USA Health December 12, 2022
LOS ANGELES — Amgen will acquire Horizon Therapeutics, a biopharmaceutical company that focuses on treatments for rare, autoimmune diseases, for about $26.4 billion. Each Horizon shareholder will receive $116.50 per share for each share they own. The deal has an enterprise... + más
About iurex | Privacy Policy | Disclaimer |